The Group
From concept to clinics. We design particle-enabled approaches to address clinical needs in disease etiology, diagnostics and drug delivery. The design specs for our particle-based solutions are given by the clinical need. We design our particle-based solutions bottom up in close exchange with our clinical collaborators as well as academic partner institutions around the world. We have expertise in particle synthesis and functionalization, characterization and imaging of particle-based systems, as well as translational nanomedicine.
We acknowledge financial support from the Swiss National Science Foundation, the Swiss Heart Foundation, the Novartis Foundation for Biomedical Research, the Novartis FreeNovation Program, the Personalized Health & Related Technologies (PHRT) Initiative, the Bangerter Rhyner Foundation, the Helmut Horten Foundation, the Swiss Heart Foundation, Krebsliga, OPO Foundation, the Olga Mayenfisch Foundation and others.
Inge Herrmann is a chemical engineer (MSc ETH Chem Bio Eng, 2007) with additional training in (pre)clinical research (incl CAS Clinical Trial Management). After graduating with a PhD from ETH Zurich in 2010 (Stark Lab), she underwent further training at the University Hospital Zurich (USZ, Beck-Schimmer Lab), the University of Illinois in Chicago (US, Minshall Lab) and the Imperial College London (UK, Stevens Lab). Since 2015, she is heading a research group at Empa specialized in the design and development of particle-enabled approaches for diagnostics and drug delivery, jointly with academic and clinical partners around the world. In 2019, Inge Herrmann joined ETH Zurich's Department of Mechanical and Process Engineering (D-MAVT) as an Assistant Professor where she is heading the Nanoparticle Systems Engineering Lab.
She is an expert in nanoparticle synthesis and characterization, microscopy and spectroscopy and translational nanomedicine. She has spearheaded several translational nanomedicine projects, and serves as a scientific advisor of the spin-off companies hemotune and nanoglue. Inge Herrmann has won various awards, including the Swiss National Science Foundation Eccellenza Award 2018, the Bayer Healthcare Award 2012 and the Johnson & Johnson Award 2012. She is principle investigator (PI) of several national and international projects supported by the Swiss National Science Foundation (Project grant and Eccellenza grant), the Personalized Health and Related Technologies Initiative (PHRT), the Novartis FreeNovation program and several medical foundations (incl. the Swiss Heart Foundation, the Bangerter Rhyner Foundation, the Horten Foundation, the Mayenfisch Foundation, etc).
